Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Advanced Solid Tumors 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Solid Tumors 1Solid Malignancies 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Leukemia 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 119Temozolomide 109Carboplatin 52Filgrastim 46Vincristine 42Etoposide 39Cyclophosphamide 36Chemotherapy, Adjuvant 36Cisplatin 35Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 23Lomustine 22Thiotepa 21Methotrexate 19Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Topotecan 12Paclitaxel 12Ifosfamide 12Drug Therapy 12Thalidomide 11Radiation 11sargramostim 10Erlotinib Hydrochloride 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Neoplasms × ST 1481 × Clear all
NCT00087061 2013-07-18

Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡